Baidu
map

Science:模拟老年痴呆的分子机制居然能治癌

2016-11-14 MedSci MedSci原创

比利时VIB鲁汶大学Switch实验室在11月11日Science上揭示了一个新设计的分子,能通过淀粉样蛋白的形成机制有效抑制癌症的发生。这项工作表明:根据淀粉样蛋白的结构可以合理地开发一种新的生物分子,能够对抗各种各样的疾病。经过十多年的研究,比利时VIB鲁汶大学Switch实验室揭示了一个新设计的分子,能通过淀粉样蛋白的形成机制有效抑制癌症的发生。这项工作表明:根据淀粉样蛋白的结构可以合理地开

比利时VIB鲁汶大学Switch实验室在11月11日Science上揭示了一个新设计的分子,能通过淀粉样蛋白的形成机制有效抑制癌症的发生。这项工作表明:根据淀粉样蛋白的结构可以合理地开发一种新的生物分子,能够对抗各种各样的疾病。


经过十多年的研究,比利时VIB鲁汶大学Switch实验室揭示了一个新设计的分子,能通过淀粉样蛋白的形成机制有效抑制癌症的发生。这项工作表明:根据淀粉样蛋白的结构可以合理地开发一种新的生物分子,能够对抗各种各样的疾病。他们在11月11日Science上发表这篇文章后,下一步要做的是将这一突破性的技术直接为患者服务。

在煮熟的鸡蛋,啤酒泡沫和蜘蛛丝的蛋白质都有一个类似的结构单元:淀粉样蛋白。这些结构也在人类中活跃,在如黑色素的生产和细胞激素储存过程中发挥作用。淀粉样蛋白也与如白内障、老年痴呆症和凝血障碍的疾病相关。由Switch实验室的Frederic Rousseau和Joost schymkowitz教授,发明了一个设计原则,可以用来摧毁基于淀粉蛋白的特性几乎任何功能。

捕捉肿瘤

这个新技术将设计好的淀粉样蛋白靶向著名的癌症靶标:血管内皮生长因子受体2(VEGFR2)。通过筛选他们确定了一个肽,被称为“vascin”,能高度有效抑制VEGFR2。很快设计的淀粉样蛋白结构的vascin就入侵细胞,从二聚体慢慢转化成淀粉样纤维,诱导靶向蛋白VEGFR2的蛋白质聚集体形成。VEGFR2开始黏在一起形成团块,让蛋白失去功能。因为VEGFR2对于某些特定的癌症的生存至关重要,它的失活可以杀死癌细胞,在小鼠中阻止肿瘤的生长。

Frederic Rousseau教授说:“我们可以把它比作一个能捕捉肿瘤的“蜘蛛网”。通过人为地模仿蛋白质团块的形成,我们可以抑制在一些疾病中发挥核心作用的分子。由于这些原则适用于几乎所有的蛋白质,我们的方法可能不是仅仅在开发未来的癌症疗法中有用,而且在治疗抗药性感染中也会有用。

新技术

研究发现一个短的淀粉样蛋白片段可以诱导与正常淀粉样蛋白不相关的变性,这种变性方式与天然淀粉样蛋白聚集的基本生理生化特性类似。

这个新技术的发明可以追溯到数年前,受到广泛的专利保护。同时,Switch实验室和其他几个研究小组合作,表明这项技术可以有很多应用,从超级细菌和真菌感染的治疗到改良作物。

Joost Schymkowitz教授说:“虽然我们还不知道功能性的淀粉样蛋白是否可用在人类做治疗应用,新药的潜力是巨大的。我们的团队将在未来几年内,试图把这一新技术转变为患者的直接利益。”

新的经营策略

与Switch实验室密切合作,VIB的技术转移团队正在积极推行这一顶级科研成果转换成社会价值。

Els Beirnaert博士(VIB新企业的高级经理)说:“这项技术新颖的作用方式、可设计性和潜在的能降低具有挑战性的细胞内疾病的目标,让这个技术成为一个有吸引力的基础,运用于开发治疗各种疾病的新的突破性药物。”

原始出处:
Rodrigo Gallardo, Meine Ramakers, Frederik De Smet, Filip Claes, Ladan。et al.De novo design of a biologically active amyloid.Science.11 Nov 2016.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1748847, encodeId=23621e488477a, content=<a href='/topic/show?id=aed164e34b5' target=_blank style='color:#2F92EE;'>#治癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64734, encryptionId=aed164e34b5, topicName=治癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0d136204823, createdName=yinhl1990, createdTime=Tue Apr 04 01:34:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156521, encodeId=c22e156521e1, content=意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636c1980460, createdName=小子慢慢来, createdTime=Fri Nov 18 06:48:06 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375387, encodeId=a75513e53872e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Nov 16 09:34:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155879, encodeId=7f641558e9f7, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 15 12:24:59 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155744, encodeId=416d155e4419, content=不错的探索, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Mon Nov 14 19:48:07 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2017-04-04 yinhl1990
  2. [GetPortalCommentsPageByObjectIdResponse(id=1748847, encodeId=23621e488477a, content=<a href='/topic/show?id=aed164e34b5' target=_blank style='color:#2F92EE;'>#治癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64734, encryptionId=aed164e34b5, topicName=治癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0d136204823, createdName=yinhl1990, createdTime=Tue Apr 04 01:34:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156521, encodeId=c22e156521e1, content=意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636c1980460, createdName=小子慢慢来, createdTime=Fri Nov 18 06:48:06 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375387, encodeId=a75513e53872e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Nov 16 09:34:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155879, encodeId=7f641558e9f7, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 15 12:24:59 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155744, encodeId=416d155e4419, content=不错的探索, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Mon Nov 14 19:48:07 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-18 小子慢慢来

    意外发现

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1748847, encodeId=23621e488477a, content=<a href='/topic/show?id=aed164e34b5' target=_blank style='color:#2F92EE;'>#治癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64734, encryptionId=aed164e34b5, topicName=治癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0d136204823, createdName=yinhl1990, createdTime=Tue Apr 04 01:34:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156521, encodeId=c22e156521e1, content=意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636c1980460, createdName=小子慢慢来, createdTime=Fri Nov 18 06:48:06 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375387, encodeId=a75513e53872e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Nov 16 09:34:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155879, encodeId=7f641558e9f7, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 15 12:24:59 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155744, encodeId=416d155e4419, content=不错的探索, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Mon Nov 14 19:48:07 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-16 jichang
  4. [GetPortalCommentsPageByObjectIdResponse(id=1748847, encodeId=23621e488477a, content=<a href='/topic/show?id=aed164e34b5' target=_blank style='color:#2F92EE;'>#治癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64734, encryptionId=aed164e34b5, topicName=治癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0d136204823, createdName=yinhl1990, createdTime=Tue Apr 04 01:34:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156521, encodeId=c22e156521e1, content=意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636c1980460, createdName=小子慢慢来, createdTime=Fri Nov 18 06:48:06 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375387, encodeId=a75513e53872e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Nov 16 09:34:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155879, encodeId=7f641558e9f7, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 15 12:24:59 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155744, encodeId=416d155e4419, content=不错的探索, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Mon Nov 14 19:48:07 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-15 李东泽

    很好,不错,以后会多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1748847, encodeId=23621e488477a, content=<a href='/topic/show?id=aed164e34b5' target=_blank style='color:#2F92EE;'>#治癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64734, encryptionId=aed164e34b5, topicName=治癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0d136204823, createdName=yinhl1990, createdTime=Tue Apr 04 01:34:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156521, encodeId=c22e156521e1, content=意外发现, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636c1980460, createdName=小子慢慢来, createdTime=Fri Nov 18 06:48:06 CST 2016, time=2016-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375387, encodeId=a75513e53872e, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Wed Nov 16 09:34:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155879, encodeId=7f641558e9f7, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Tue Nov 15 12:24:59 CST 2016, time=2016-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155744, encodeId=416d155e4419, content=不错的探索, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Mon Nov 14 19:48:07 CST 2016, time=2016-11-14, status=1, ipAttribution=)]
    2016-11-14 Peter程

    不错的探索

    0

相关资讯

Science子刊:Verubecestat-新型抗阿尔茨海默症药物,有望引发治疗新变革

一种靶向于脑中的淀粉样蛋白(阿尔茨海默病的主要标志物之一)的新型药物在一项小规模临床试验中取得了可喜的成果,同时,这一成果正在于两项涉及3500人的大型研究中进行评估。如果这种以片剂形式服用的药物确实被证实能缓解阿尔茨海默氏症带来的严重记忆力衰退,那么这种药物将会是未来十年内进入市场的首个治疗方法。

盘点:9月老年痴呆研究进展,值得一看

老年性痴呆又称阿尔茨海默病,是一种原因未明的进行性脑变性疾病,通常发生在65岁以上的老年人中,以记忆障碍为最初表现,之后逐渐出现语言、定向、思维、计算、运动等功能受损,日常生活能力不断下降,最终不能独立生活。本文梅斯医学小编整理了9月有关老年痴呆相关研究进展,与大家分享。【1】阿尔茨海默病治疗新希望:PRIME研究结果正式发布近日,PRIME研究1b期正式结果显示,阿尔茨海默病治疗试验药物ad

盘点:近期老年痴呆研究进展,值得一看

老年性痴呆又称阿尔茨海默病,是一种原因未明的进行性脑变性疾病,通常发生在65岁以上的老年人中,以记忆障碍为最初表现,之后逐渐出现语言、定向、思维、计算、运动等功能受损,日常生活能力不断下降,最终不能独立生活。本文梅斯医学小编整理了9月有关老年痴呆相关研究进展,与大家分享。【1】Cell子刊:老年痴呆的致病蛋白,或许可以用于治疗癌症十月初,科学家对淀粉样蛋白又有了“好”的发现。来自于迈阿密大学米

Neuroepidemiology:牙周病患者日后老年痴呆的发生风险较高

慢性牙周炎和牙龈炎与很多疾病具有相关性,然而,它们对老年痴呆的影响尚未阐明。该研究旨在观察慢性牙周炎和牙龈炎与老年痴呆发生风险之间的关系。 研究共纳入来自台湾国家健康保险研究数据库的2207名患者,这些患者在2000年1月1日至2000年12月31日之间刚刚被诊断为慢性牙周炎和牙龈炎,还纳入了性别和年龄相匹配的6621名对照。调整混杂因素后,使用Cox比例风险模型分析比较10年随访期间发生老

Baidu
map
Baidu
map
Baidu
map